TEVA
Teva Pharmaceutical Industries Limited American Depositary Shares
$37.33
장중 · Vol 544.2K · 52주 $18.14–$38.37 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $35.84 · Aug 31, 2026
TEVA 가격 추세
종가
$35.84
시가
$36.17
고가
$36.12
저가
$35.62
30초 브리핑
TEVA 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 95%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E 11.8배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 0.8배
거래량은 최근 평균 범위입니다.
2026-11-04
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Aug 31, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
TEVA 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Aug 31, 2026
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
124 Dvora HaNevi’a St. · Tel Aviv-Yafo, Israel · 직원 31,173명
시가총액
$42.46B
Trailing P/E
60.7
최근 12개월 이익 기준
Forward P/E
11.8
이익 증가 기대 반영
EPS (TTM)
$0.60
배당 수익률
—
배당성향
0.0%
베타
0.88
시장과 유사
ROE
9.7%
P/B
5.48
EV/EBITDA
13.1
52주 범위
$18.14 – $38.37
현재 위치 95%
거래량
2.80M
20일 평균 3.66M · 0.8배
애널리스트 의견
매수 92%
총 12명 · 0m
DITM LEAPS Analysis
TEVA 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TEVA280121C00020000 | 1/21/28 · 1.4Y | $20.00 | $17.72 | 1.8x | 0.9055 | 10.0% | 4.80% | 55.98% | 938 | 87.23 | |
| TEVA280121C00022000 | 1/21/28 · 1.4Y | $22.00 | $16.18 | 2.0x | 0.8825 | 13.7% | 5.26% | 54.10% | 207 | 81.90 | |
| TEVA280121C00025000 | 1/21/28 · 1.4Y | $25.00 | $13.92 | 2.2x | 0.8434 | 21.3% | 6.10% | 51.07% | 505 | 75.78 | |
| TEVA280121C00027000 | 1/21/28 · 1.4Y | $27.00 | $12.52 | 2.3x | 0.8085 | 28.5% | 6.79% | 52.76% | 901 | 69.33 | |
| TEVA280121C00030000 | 1/21/28 · 1.4Y | $30.00 | $10.58 | 2.6x | 0.7614 | 43.6% | 5.20% | 49.04% | 624 | 58.68 |
재무제표
TEVA 연간 손익·현금흐름·재무상태
매출 성장률
+4.3%
최근 연간 YoY
EPS 성장률
+183.4%
최근 연간 YoY
영업이익률
22.9%
최근 연간
FCF 마진
6.7%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $17.26B+4.3% | $16.54B+4.4% | $15.85B+6.2% | $14.93B |
| 매출총이익 | $8.94B+10.8% | $8.06B+5.5% | $7.64B+9.6% | $6.97B |
| 영업이익 | $3.95B+17.5% | $3.36B+5.3% | $3.19B+18.7% | $2.69B |
| 순이익 | $1.41B+186.0% | -$1.64B-193.2% | -$559.00M+77.1% | -$2.45B |
| 희석 EPS | $1.21+183.4% | $-1.45-190.0% | $-0.50+76.4% | $-2.12 |
| EBITDA | $3.14B+304.2% | $777.00M-50.1% | $1.56B+268.4% | -$925.00M |
| 영업현금흐름 | $1.65B+32.2% | $1.25B-8.8% | $1.37B-14.0% | $1.59B |
| 잉여현금흐름 | $1.15B+53.3% | $749.00M-11.0% | $842.00M-19.2% | $1.04B |
| 총자산 | $40.75B+3.6% | $39.33B-9.6% | $43.48B-1.2% | $44.01B |
| 총부채 | $17.09B-5.4% | $18.08B-10.3% | $20.15B-6.5% | $21.56B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
TEVA 실적·배당 일정
매출 하단
$4.04B
EPS 하단
$0.60
매출 상단
$4.37B
배당 지급일
2017-12-12
3185일 전
실적 발표일
2026-11-04
D-64
EPS 상단
$0.74
매출 컨센서스
$4.23B
EPS 컨센서스
$0.71
배당락일
2017-11-27
3200일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Nov 27, 2017 | $0.0850 |
| Aug 25, 2017 | $0.0850 |
| Jun 1, 2017 | $0.3400 |
| Feb 28, 2017 | $0.3400 |
| Dec 1, 2016 | $0.3400 |
| Aug 18, 2016 | $0.3400 |
| May 20, 2016 | $0.3400 |
| Feb 25, 2016 | $0.3400 |
뉴스
TEVA 관련 최신 기사
M&AWhat Is Teva Pharmaceutical Industries (TEVA) Gaining From This Bankruptcy Drug Deal?
Teva Pharmaceutical Industries (NYSE:TEVA) agreed to acquire BioXcel Therapeutics' dexmedetomidine sublingual film for at-home treatment of agitation in schizophrenia and bipolar disorder through a bankruptcy asset sale process. The transaction is subject to approval by the bankruptcy court, potential competing bids, and standard closing conditions before Teva can assume full rights to the asset. The dexmedetomidine sublingual film is under FDA review for at-home use. This transaction is...
Simply Wall St. · Aug 30, 2026
- 규제·법률
Teva Pharmaceutical Industries (TEVA) Could Be 11% Undervalued As FDA Accepts Ecopipam Filing
Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, a first in class pediatric Tourette syndrome treatment. Despite the share price easing around 3% over the last day and 2% over the past week, Teva Pharmaceutical Industries has a 1 month share price return of about 4% and a year to date share price return of around 18%, while total shareholder return over the past year is close to 100%. This...
Simply Wall St. · Aug 30, 2026
- 실적
Teva (TEVA) Stock Looks Below Fair Value While Earnings Sit Above Fair Value
Teva Pharmaceutical Industries stock has delivered a very strong 284.4% gain over the past 5 years, yet current checks send mixed signals as the Discounted Cash Flow (DCF) estimate points to undervaluation while market based multiples screen the shares as expensive. Investors looking at Teva today see a stock with powerful recent momentum against a low overall value score that suggests it is not a straightforward bargain. A 284.4% return over 5 years highlights how much Teva has already...
Simply Wall St. · Aug 30, 2026
제품·기술Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurinia’s patents covering its flagship oral lupus nephritis drug, LUPKYNIS, are valid, enforceable, and infringed by its proposed generic 7.9 mg voclosporin product. Teva agreed to delay generic commercialization until […]
Insider Monkey · Aug 28, 2026
- 제품·기술
BioXcel Therapeutics Enters Asset Sale Agreement With Teva Pharmaceuticals
BioXcel Therapeutics (BTAI) has entered into an agreement with Teva Pharmaceutical Industries (TEVA)
MT Newswires · Aug 28, 2026
제품·기술Are Wall Street Analysts Predicting Deckers Outdoor Stock Will Climb or Sink?
Deckers Outdoor has lagged the broader market over the past year, with analysts remaining cautiously optimistic about its future prospects.
Barchart · Aug 27, 2026
일반NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
Zacks · Aug 25, 2026
규제·법률TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome
Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.
Zacks · Aug 20, 2026
- 일반
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
Zacks · Aug 20, 2026
- 일반
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?
NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.
Zacks · Aug 20, 2026
홀더
TEVA 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
64.5%
기관 보유 (유동주식)
64.5%
내부자 보유
0.0%
기관 수
915
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 63.89M | $2.33B | 5.5% | -1.9% | Jun 30, 2026 |
| Harel Insurance Investments & Financial Services Ltd. | 48.14M | $1.75B | 4.1% | 4.8% | Jun 30, 2026 |
| Phoenix Financial Ltd. | 42.93M | $1.56B | 3.7% | 0.4% | Jun 30, 2026 |
| WCM Investment Management, LLC | 41.32M | $1.51B | 3.5% | 1.2% | Jun 30, 2026 |
| Clal Insurance Enterprises Holdings Ltd | 40.60M | $1.48B | 3.5% | 5.6% | Jun 30, 2026 |
| Menora Mivtachim Holdings Ltd. | 39.85M | $1.45B | 3.4% | 0.6% | Jun 30, 2026 |
| Migdal Insurance & Financial Holdings Ltd. | 38.92M | $1.42B | 3.3% | 2.7% | Jun 30, 2026 |
| NORGES BANK | 32.30M | $1.18B | 2.8% | -8.2% | Jun 30, 2026 |
| FMR, LLC | 30.26M | $1.10B | 2.6% | -8.7% | Jun 30, 2026 |
| Lingotto Investment Management LLP | 20.21M | $736.30M | 1.7% | -27.2% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.
.png&w=3840&q=75)